Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.
暂无分享，去创建一个
R. Schilsky | F. Meric-Bernstam | E. Garrett-Mayer | S. Halabi | E. Ahn | Ranju Gupta | S. D’Andre | P. K. Mangat | R. O'Lone | M. Rothe | G. N. Grantham | R. O’Lone | P. Mangat | S. D'Andre